EMA – Strengthening supply chain of anti-D immunoglobulins
EMA and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), have issued recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins.
These medicines are currently the only available treatment for the prevention of RhD immunisation during pregnancy. RhD immunisation happens when a pregnant person with RhD-negative blood type is exposed to RhD-positive blood from their foetus. This can lead to an immune reaction that can seriously impact the health of the foetus, and later of the newborn, and have potentially fatal outcomes.
More information on the EMA Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (20 septembre 2025). EMA – Strengthening supply chain of anti-D immunoglobulins. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/14pwd





